<?xml version="1.0" encoding="UTF-8"?>
<p id="p0250">Russell et al. recommended that corticosteroids should not be used in SARS-CoV-2–induced lung injury or shock.
 <xref rid="bib49" ref-type="bibr">
  <sup>49</sup>
 </xref> However, Shang et al. suggested using short courses (≤ 7 days) of corticosteroids at low to moderate dose (≤ 0.5-1 mg/kg/d methylprednisolone or equivalent) for critically ill patients with COVID-19.
 <xref rid="bib50" ref-type="bibr">
  <sup>50</sup>
 </xref> According to a Chinese experts’ consensus statement, the following criteria should be met before using corticosteroids in patients with COVID-19: 1) adults (≥ 18 years old), 2) laboratory-confirmed cases, 3) symptoms occurring within 10 days, 4) radiographic imaging consistent with COVID-19 pneumonia and progressing rapidly, and 5) SPO
 <sub>2</sub> ≤ 93%, shortness of breath (respiratory rate ≥ 30/min), or oxygenation index ≤ 300 mm Hg at rest and with no oxygen therapy.
 <xref rid="bib51" ref-type="bibr">
  <sup>51</sup>
 </xref>
</p>
